Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buloxibutid in idiopathic pulmonary fibrosis
2023-509069-19-00Phase 2Authorised
- Sponsor
- Vicore Pharma
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of buloxibutid in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Vicore Pharma. Primary endpoint: Absolute change from baseline in FVC (mL) at Week 52. Planned start Nov 2024; status: authorised.
02
Drugs
buloxibutid
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2023-509069-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509069-19-00.